Eli Lilly (LLY) Research & Development (2009 - 2026)

Eli Lilly (LLY) has reported Research & Development for 18 consecutive years, with $3.5 billion the latest figure, recorded in Q1 2026.

• Research & Development for Q1 2026 came in at $3.5 billion, up 28.38% year-over-year; the trailing twelve-month figure through Mar 2026 was $14.1 billion (up 25.99% YoY), and the FY2025 annual result was $13.3 billion, up 21.34% from the prior year.
• Research & Development was $3.5 billion for Q1 2026 at Eli Lilly, down from $3.8 billion in the prior quarter.
• Over five years, Research & Development peaked at $3.8 billion in Q4 2025 and troughed at $1.6 billion in Q1 2022.
• Average Research & Development over 5 years is $2.6 billion, with a median of $2.6 billion recorded in 2023.
• Year-over-year, Research & Development fell 3.71% in 2022 and soared 33.62% in 2023.
• Over 5 years, Research & Development stood at $2.0 billion in 2022, then rose by 28.38% to $2.6 billion in 2023, then gained by 17.98% to $3.0 billion in 2024, then increased by 25.76% to $3.8 billion in 2025, then fell by 7.67% to $3.5 billion in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $3.5 billion in Q1 2026, $3.8 billion in Q4 2025, and $3.5 billion in Q3 2025.